HumanZyme Inc. now offers recombinant human Wnt3A expressed in human cells, a new addition to their HumanKine product line.
Chicago, IL (PRWEB) December 13, 2016
HumanZyme Inc., a leading supplier of novel human proteins and growth factors expressed in human cells today announced the launch of Wnt3A, a new addition to their HumanKine® authentic recombinant human protein product line. Wnt3a is a widely used reagent for the in vitro self-renewal and differentiation of human embryonic stem cell cultures, and is an important tool for stem cell and cell therapy researchers.
According to Scott Coleridge, CEO at HumanZyme, “This is a very difficult protein to make and we are quite proud to be one of the very few companies to offer human cell-produced Wnt3A. Our R&D team worked very hard to make this possible. Wnt3A is an important addition to our high-quality HumanKine authentic recombinant human cytokines and growth factors used for stem cell expansion, differentiation and maintenance. The new Wnt3A product is priced competitively, is animal-derived product free and available in bulk.”
Wnt3A is a highly-conserved, cysteine-rich glycosylated protein whose biological activity is dependent on correct glycosylation and acylation. Expression of Wnt3A in human cells with native processing, glycosylation and folding ensures native activity compared to other expression systems such as bacterial, mammalian cell lines, or insect cells. HumanZyme’s HumanKine proteins are also animal-free, xeno-free and carrier-free. The new Wnt3A offering expands the HumanKine product line of recombinant human proteins expressed in human cells available from HumanZyme.
For more information, see our Wnt3A product page.
About HumanZyme, Inc.
HumanZyme, Inc. is the global leader in providing highly authentic recombinant human proteins from human cells. Our process is cost-effective and scalable making our proteins suitable for the research, diagnostic, drug discovery and biopharmaceutical markets. HumanZyme leverages its proprietary HumaXpress engineered human cells, expression vector, and cell culture media to ensure high-yield production of recombinant proteins with native human post-translational modifications. We are a leading provider of cytokines and growth factors and a preferred outsourcing supplier of human protein production. Our products and services support a broad range of customers worldwide—from academic and government research institutions to biotechnology and pharmaceutical companies.
For the original version on PRWeb visit: http://www.prweb.com/releases/2016/12/prweb13920846.htm